MCID: NWB001
MIFTS: 59

Newborn Respiratory Distress Syndrome

Categories: Fetal diseases, Respiratory diseases

Aliases & Classifications for Newborn Respiratory Distress Syndrome

MalaCards integrated aliases for Newborn Respiratory Distress Syndrome:

Name: Newborn Respiratory Distress Syndrome 39 12 15 17
Hyaline Membrane Disease 12 56 45 74
Neonatal Respiratory Distress 30 6
Pulmonary Hypoperfusion Syndrome of Newborn 12
Respiratory Distress Syndrome of Newborn 12
Neonatal Respiratory Distress Syndrome 12
Respiratory Distress Syndrome, Newborn 74
Pulmonary Hyaline Membrane Disease 12
Hmd - Hyaline Membrane Disease 12
Respiratory Distress Syndrome 74

Classifications:



External Ids:

Disease Ontology 12 DOID:12716
MeSH 45 D006819
SNOMED-CT 69 26168007 46775006
ICD10 34 P22.0

Summaries for Newborn Respiratory Distress Syndrome

Disease Ontology : 12 A respiratory failure that is characterized by deficiency of the surfactant coating the inner surface of the lungs, by failure of the lungs to expand and contract properly during breathing with resulting collapse, and by the accumulation of a protein-containing film lining the alveoli and their ducts.

MalaCards based summary : Newborn Respiratory Distress Syndrome, also known as hyaline membrane disease, is related to respiratory distress syndrome in premature infants and bronchopulmonary dysplasia, and has symptoms including dyspnea, respiratory distress and apnea. An important gene associated with Newborn Respiratory Distress Syndrome is BRAF (B-Raf Proto-Oncogene, Serine/Threonine Kinase), and among its related pathways/superpathways are Bacterial infections in CF airways and Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways. The drugs Infasurf and Midazolam have been mentioned in the context of this disorder. Affiliated tissues include Lung and Lung, and related phenotypes are homeostasis/metabolism and growth/size/body region

Related Diseases for Newborn Respiratory Distress Syndrome

Diseases related to Newborn Respiratory Distress Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 174)
# Related Disease Score Top Affiliating Genes
1 respiratory distress syndrome in premature infants 31.1 ABCA3 SFTPB SFTPC
2 bronchopulmonary dysplasia 30.7 CXCL8 ELANE SCGB1A1 SFTPB
3 tracheal agenesis 30.4 SFTPB SFTPD
4 funisitis 30.3 CXCL8 IL1B IL6
5 pulmonary alveolar proteinosis 30.2 SFTPB SFTPC SFTPD
6 preterm premature rupture of the membranes 30.0 CXCL8 IL1B IL6
7 chorioamnionitis 29.7 CXCL8 ELANE IL1B IL6
8 bacterial pneumonia 29.6 CXCL8 ELANE IL6 SFTPB SFTPD
9 pneumonia 29.5 CXCL8 ELANE IL1B IL6 SFTPB SFTPC
10 adult respiratory distress syndrome 29.4 CXCL8 ELANE IL6 SFTPB SFTPC TF
11 lung disease 28.8 ABCA3 CXCL8 ELANE IL1B IL6 SFTPB
12 acute respiratory distress syndrome 27.4 CXCL8 ELANE F5 HBG2 IL1B IL6
13 choreoathetosis and congenital hypothyroidism with or without pulmonary dysfunction 12.0
14 kartagener syndrome 11.5
15 ciliary dyskinesia, primary, 26 11.3
16 ciliary dyskinesia, primary, 27 11.3
17 ciliary dyskinesia, primary, 9 11.1
18 ciliary dyskinesia, primary, 38 11.1
19 paraquat lung 10.5 SCGB1A1 SFTPB
20 toxic pneumonitis 10.4 SCGB1A1 SFTPB
21 exudative glomerulonephritis 10.4 CXCL8 IL1B
22 pulmonary immaturity 10.3 SFTPB SFTPC SFTPD
23 pulmonary fibrosis 10.3 IL1B SFTPC SFTPD
24 desquamative interstitial pneumonia 10.3 ABCA3 SFTPC
25 interstitial emphysema 10.3
26 neonatal respiratory failure 10.3 ABCA3 SFTPB SFTPC
27 haemophilus influenzae 10.2 CXCL8 IL1B TF
28 autoimmune vasculitis 10.2 ELANE IL1B
29 pulmonary emphysema 10.2 ELANE SFTPC SFTPD
30 acute transverse myelitis 10.2 CXCL8 IL6
31 streptococcal toxic-shock syndrome 10.2 CXCL8 IL6
32 periodontitis, chronic 10.2 IL1B IL6
33 peptic esophagitis 10.2 CXCL8 IL1B
34 ligneous conjunctivitis 10.2 ELANE PLG
35 patent ductus arteriosus 1 10.2
36 bronchiolitis obliterans 10.2 CXCL8 IL6 SCGB1A1
37 avian influenza 10.2 CXCL8 IL6 SFTPD
38 denture stomatitis 10.2 CXCL8 IL6
39 recurrent corneal erosion 10.2 CXCL8 IL1B IL6
40 bagassosis 10.2 CXCL8 IL1B IL6
41 cardiomyopathy, familial hypertrophic, 9 10.2 TF TTN
42 eales disease 10.2 IL1B IL6 TF
43 respiratory distress syndrome, infant 10.2
44 endometrial disease 10.2 CXCL8 IL1B IL6
45 vaginal disease 10.2 CXCL8 IL1B IL6
46 vaginitis 10.2 CXCL8 IL1B IL6
47 pulpitis 10.1 CXCL8 IL1B IL6
48 middle ear disease 10.1 CXCL8 IL1B IL6
49 viral encephalitis 10.1 CXCL8 IL1B IL6
50 prostatitis 10.1 CXCL8 IL1B IL6

Graphical network of the top 20 diseases related to Newborn Respiratory Distress Syndrome:



Diseases related to Newborn Respiratory Distress Syndrome

Symptoms & Phenotypes for Newborn Respiratory Distress Syndrome

UMLS symptoms related to Newborn Respiratory Distress Syndrome:


dyspnea, respiratory distress, apnea, hemoptysis, cheyne-stokes respiration, coughing, hoarseness

MGI Mouse Phenotypes related to Newborn Respiratory Distress Syndrome:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.13 ABCA3 BRAF ELANE F5 IGHMBP2 IL1B
2 growth/size/body region MP:0005378 10.11 BRAF F5 IGHMBP2 IL1B IL6 PLG
3 cardiovascular system MP:0005385 10.06 ABCA3 BRAF F5 IGHMBP2 IL1B IL6
4 mortality/aging MP:0010768 10.03 ABCA3 BRAF ELANE F5 IGHMBP2 IL1B
5 immune system MP:0005387 9.96 BRAF ELANE IL1B IL6 PLA2G7 PLG
6 neoplasm MP:0002006 9.5 BRAF ELANE IL1B IL6 PLG SCGB1A1
7 respiratory system MP:0005388 9.28 ABCA3 BRAF IGHMBP2 IL6 PLG SCGB1A1

Drugs & Therapeutics for Newborn Respiratory Distress Syndrome

FDA approved drugs:

# Drug Name Active Ingredient(s) 19 Company Approval Date
1
Infasurf 19 CALFACTANT ONY July 1998

Drugs for Newborn Respiratory Distress Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 495)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Midazolam Approved, Illicit Phase 4,Phase 3,Not Applicable 59467-70-8 4192
2
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 2078-54-8 4943
3
Remifentanil Approved Phase 4,Not Applicable,Early Phase 1 132875-61-7 60815
4
Cisatracurium Approved Phase 4,Phase 3,Early Phase 1 96946-41-7
5
Epinephrine Approved, Vet_approved Phase 4,Phase 2 51-43-4 5816
6
Hydrocortisone acetate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-03-3
7
Racepinephrine Approved Phase 4,Phase 2 329-65-7 838
8
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-23-7 5754
9
Budesonide Approved Phase 4,Phase 2,Not Applicable 51333-22-3 5281004 63006
10 Beractant Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 108778-82-1
11 Poractant alfa Approved Phase 4,Phase 2,Phase 3,Not Applicable 129069-19-8
12
Tramadol Approved, Investigational Phase 4,Not Applicable 27203-92-5 33741
13
Ropivacaine Approved Phase 4,Phase 3 84057-95-4 175805 71273
14
Sufentanil Approved, Investigational Phase 4,Phase 3,Early Phase 1 56030-54-7 41693
15
Nefopam Approved, Investigational Phase 4 13669-70-0
16
Acetaminophen Approved Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1 103-90-2 1983
17
Clonidine Approved Phase 4 4205-90-7 2803
18
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 302-25-0
19
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 50-24-8 5755
20
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 83-43-2 6741
21
Methylprednisolone hemisuccinate Approved Phase 4,Phase 2,Phase 3,Not Applicable 2921-57-5
22
Povidone-iodine Approved Phase 4,Phase 3,Phase 2 25655-41-8
23
Metformin Approved Phase 4,Phase 2,Phase 3,Not Applicable 657-24-9 14219 4091
24
Atracurium Approved, Experimental, Investigational Phase 4,Not Applicable 64228-79-1 47319
25
Cefuroxime Approved Phase 4 55268-75-2 5479529 5361202
26
Metronidazole Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 443-48-1 4173
27
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
28
Carbon monoxide Approved, Investigational Phase 4,Phase 2,Phase 1 630-08-0 281
29
Atropine Approved, Vet_approved Phase 4,Phase 1,Not Applicable 5908-99-6, 51-55-8 174174
30
Betamethasone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 378-44-9 9782
31
tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1401-55-4
32
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1994-09-7, 94-09-7 2337
33
Progesterone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 57-83-0 5994
34
Zinc Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 7440-66-6 32051
35
Ketamine Approved, Vet_approved Phase 4,Phase 3,Not Applicable 6740-88-1 3821
36
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-02-2 5743
37
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 1177-87-3
38
Morphine Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 57-27-2 5288826
39
Sevoflurane Approved, Vet_approved Phase 4,Early Phase 1 28523-86-6 5206
40
Rocuronium Approved Phase 4,Not Applicable,Early Phase 1 119302-91-9, 143558-00-3 441290
41
Succinylcholine Approved Phase 4 306-40-1 5314
42
Cetrorelix Approved, Investigational Phase 4 120287-85-6 25074887 16129715
43
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 113775-47-6 5311068 68602
44
Nifedipine Approved Phase 4,Phase 3,Not Applicable 21829-25-4 4485
45
Sodium Citrate Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 68-04-2
46
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 1,Not Applicable,Early Phase 1 437-38-7 3345
47
Iron Approved, Experimental Phase 4 7439-89-6, 15438-31-0 27284 23925
48
Labetalol Approved Phase 4 36894-69-6 3869
49
Misoprostol Approved Phase 4,Not Applicable 59122-46-2 5282381
50
Caffeine Approved Phase 4,Not Applicable,Early Phase 1 58-08-2 2519

Interventional clinical trials:

(show top 50) (show all 1306)
# Name Status NCT ID Phase Drugs
1 Propofol Versus Midazolam as Premedication for Preterm Neonates With Respiratory Distress Syndrome (RDS) Unknown status NCT00797160 Phase 4 propofol
2 Impact of Fluid Resuscitation Therapy on Pulmonary Edema as Measured by Alveolar Fluid Clearance in Patients With Acute Respiratory Distress Syndrome (ARDS) Unknown status NCT01763853 Phase 4 4% albumin
3 Efficacy Evaluation of Surfactant Administration Via Laryngeal Mask Airway Unknown status NCT01173237 Phase 4
4 Effects of Neuromuscular Blocking Agents (NMBA) on the Alteration of Transpulmonary Pressures at the Early Phase of Acute Respiratory Distress Syndrome (ARDS) Unknown status NCT01573715 Phase 4 NIMBEX;NIMBEX
5 Early CPAP in Respiratory Distress Syndrome Unknown status NCT00368680 Phase 4
6 Effect of Treatment With Stress-Doses Glucocorticoid in Patients With Acute Respiratory Distress Syndrome (ARDS) Unknown status NCT00773058 Phase 4 hydrocortisone;placebo
7 Two Strategies of RDS Treatment in Newborns With Birth Weight > 1500 Grams Unknown status NCT00277030 Phase 4 Surfactant
8 SLI MANEUVER and RESPIRATORY MORBIDITIES Unknown status NCT02887924 Phase 4
9 Prevention of Chronic Lung Disease (CLD) in Preterm Infants Unknown status NCT00883532 Phase 4 budesonide;surfactant and air (placebo)
10 Brain Oxygenation and Function of Preterm Newborns During Administration of Two Different Surfactant Preparations Unknown status NCT01941524 Phase 4 Poractant alfa instillation;Beractant instillation
11 Surfactant Administration During Spontaneous Breathing Unknown status NCT01329432 Phase 4
12 Epidural Analgesia for Pancreatitis (Epipan Study) Unknown status NCT02126332 Phase 4
13 The Study of Using Esophageal Pressure to Guide the PEEP Setting in Abdominal Hypertension Patients Who Undergoing Mechanical Ventilation Unknown status NCT01825304 Phase 4
14 6-Methyl-Prednisolone for Multiple Organ Dysfunction Syndrome Unknown status NCT00127985 Phase 4 6-methyl-prednisolone
15 Neurally Adjusted Ventilatory Assist (NAVA) vs. Pressure Support in Pediatric Acute Respiratory Failure Unknown status NCT01873521 Phase 4
16 FRC Guided Therapy in Acute Respiratory Failure Unknown status NCT01280019 Phase 4
17 Cervical Cerclage for Preventing Spontaneous Preterm Birth in Singleton Pregnancies Without Prior Spontaneous Preterm Birth and With Short Transvaginal Ultrasound Cervical Length Unknown status NCT02746900 Phase 4
18 Preventing Recurrent Gestational Diabetes With Metformin Unknown status NCT02394158 Phase 4 Metformin;placebo
19 Treatment of Intracranial Hypertension of Severe Tramatic Brain Injured Patients. Physiopathologic Effects of Neuromuscular Blocking Agents Unknown status NCT02404779 Phase 4 cisatracurium besilate
20 Parenteral Antibiotics Compared to Combination of Oral and Parenteral Antibiotics in Colorectal Surgery Prophylaxis Unknown status NCT02505581 Phase 4 Extra dosage - cefuroxime (750mg) I.V;Cefuroxime 750mg oral;Metronidazole 250mg oral;Metronidazole 1,5gr Intravenous;Cefuroxime 1g Intravenous
21 Comparison of Nasal CPAP and Nasal SIMV in Transient Tachypnea of Newborn Unknown status NCT01499238 Phase 4
22 Comparative Study of Non-Invasive Mask Ventilation vs Cuirass Ventilation in Patients With Acute Respiratory Failure. Unknown status NCT00331656 Phase 4
23 Corticosteroid Mediates Acute Respiratory Distress Syndrome Completed NCT02819453 Phase 4 Methylprednisolone
24 Efficacy Study of Dexamethasone to Treat the Acute Respiratory Distress Syndrome Completed NCT01731795 Phase 4 Dexamethasone
25 Remifentanil Versus Morphine for Sedation of Premature Neonates With Respiratory Distress Syndrome Completed NCT00391105 Phase 4 Remifentanil
26 Effects of Bolus Surfactant Therapy on Peripheral Perfusion Index and Tissue Carbon Monoxide Completed NCT01923844 Phase 4 exogenous surfactant
27 Diffuse Acute Respiratory Distress Syndrome (ARDS), Recruitment Maneuver, and sRAGE (DAMAGE Study) Completed NCT01600651 Phase 4
28 Randomized Controlled Trial of Surfactant Delivery Via Laryngeal Mask Airway (LMA) Versus Endotracheal Intubation Completed NCT01042600 Phase 4
29 Effects of SEvoflurane on Gas Exchange and Inflammation in Patients With ARDS (SEGA Study) Completed NCT02166853 Phase 4 sevoflurane;midazolam
30 Efficacy of Combining Prophylactic Curosurf With Early Nasal CPAP in Delivery Room: the Curpap Study Completed NCT00501982 Phase 4 Poractant alfa (Curosurf®)
31 Caesarean and Corticotherapy Completed NCT00446953 Phase 4 betamethasone
32 Comparison of Effectiveness of Nasal CPAP and Nasal IMV in Early Rescue Surfactant Treatment in Preterm Infants Completed NCT01741129 Phase 4
33 Premedication for Non-Emergency Endotracheal Intubation In the NICU Completed NCT01749501 Phase 4 Rocuronium
34 Synchronized Intermittent Mandatory Ventilation (SIMV) Versus Nasal Intermittent Positive Pressure Ventilation (NIPPV) In Preterm Infants With Respiratory Distress Completed NCT00486850 Phase 4
35 Effect of Neuromuscular Blockade on Pulmonary Complications in Elective Cardiac Surgery Completed NCT02635542 Phase 4 Succinylcholine;Cisatracurium
36 Effect of Perioperative Lung Protective Strategies on the Occurrence of Postoperative Pulmonary Complications in Patients Undergoing Lumbar Spinal Surgery in the Prone Position Completed NCT02373475 Phase 4
37 Vaginal Progesterone for Prevention of Preterm Labor in Asymptomatic Twin Pregnancies With Sonographic Short Cervix Completed NCT02338830 Phase 4 Progesterone
38 Steroids in Bilateral Total Knee Replacement Completed NCT01399268 Phase 4 Hydrocortisone;Saline
39 On Versus Off Pump Myocardial Revascularization Study Completed NCT01290952 Phase 4
40 Restrictive vs. Liberal Oxygen Therapy for Trauma Patients Completed NCT03491644 Phase 4 Titrated Oxygen;Liberal Oxygen
41 A Randomized Trial Comparing the Impact of One Versus Two Courses of Antenatal Steroids (ACS) on Neonatal Outcome Completed NCT00201643 Phase 4 Betamethasone or Dexamethasone (2nd course of ACS);Placebo
42 The Study of Pharmacokinetics and Pharmacodynamics of Cisatracurium Completed NCT03337373 Phase 4 cisatracurium
43 Non-Positive Pressure Ventilation in Hypoxemic Patients Completed NCT00925860 Phase 4
44 Efficacy of 17 Alpha-hydroxyprogesterones Caproate for the Prevention of Preterm Delivery Completed NCT00331695 Phase 4 17 alpha-hydroxyprogesterones caproate
45 Preventing Cardiovascular collaPse With Administration of Fluid Resuscitation Before Endotracheal Intubation Completed NCT03026777 Phase 4 intravenous crystalloid fluid, 500 mL
46 Long Protocol and Freeze All Embryos vs Antagonist Protocol With Fresh Embryo Transfer in PCOS Patients Undergoing ICSI Completed NCT03118830 Phase 4 Triptorelin;cetrorelix;Recombinant Follicle Stimulating Hormone
47 Evaluation of Use of Plastic Bags to Prevent Neonatal Hypothermia-Part IV Completed NCT01604447 Phase 4
48 Evaluate the Use of Plastic Bags in Preventing and Treating Hypothermia in Neonates Completed NCT01403623 Phase 4
49 Intraoperative Protective Ventilation in Abdominal Surgery (IMPROVE Study) Completed NCT01282996 Phase 4
50 Study of Sivelestat Sodium Hydrate in Acute Lung Injury (ALI) Associated With Systemic Inflammatory Response Syndrome (SIRS) in Japan Completed NCT00219375 Phase 4 Sivelestat sodium hydrate;Sivelestat sodium hydrate

Search NIH Clinical Center for Newborn Respiratory Distress Syndrome

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: hyaline membrane disease

Genetic Tests for Newborn Respiratory Distress Syndrome

Genetic tests related to Newborn Respiratory Distress Syndrome:

# Genetic test Affiliating Genes
1 Neonatal Respiratory Distress 30

Anatomical Context for Newborn Respiratory Distress Syndrome

MalaCards organs/tissues related to Newborn Respiratory Distress Syndrome:

42
Lung, Brain, Cervix, Testes, Liver, Heart, Fetal Lung
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Newborn Respiratory Distress Syndrome:
# Tissue Anatomical CompartmentCell Relevance
1 Lung Alveoli Alveolar Epithelial Type 1 Cells Affected by disease, potential therapeutic candidate
2 Lung Alveoli Alveolar Epithelial Type 2 Cells Affected by disease, potential therapeutic candidate
3 Lung Pulmonary Capillary Plexus Affected by disease

Publications for Newborn Respiratory Distress Syndrome

Articles related to Newborn Respiratory Distress Syndrome:

(show top 50) (show all 599)
# Title Authors Year
1
Co-initiation of continuous renal replacement therapy, peritoneal dialysis, and extracorporeal membrane oxygenation in neonatal life-threatening hyaline membrane disease: A case report. ( 30681590 )
2019
2
Hyaline membrane disease (HMD): an historical and Oslerian perspective. ( 30291319 )
2018
3
50 years ago in the Journal of Pediatrics: surface properties and lipids from lungs of infants with hyaline membrane disease. ( 25620514 )
2015
4
Diagnostic value of gastric shake test for hyaline membrane disease in preterm infant. ( 25114671 )
2014
5
High frequency oscillatory ventilation versus synchronized intermittent mandatory ventilation in preterm neonates with hyaline membrane disease: a randomized controlled trial. ( 22700666 )
2012
6
Nuclear factor kappaB activation in pulmonary leukocytes from infants with hyaline membrane disease: associations with chorioamnionitis and Ureaplasma urealyticum colonization. ( 15746262 )
2005
7
Intrauterine tobacco smoke exposure and hyaline membrane disease amongst triplets. ( 16147688 )
2005
8
Deficient Na+ channel expression in newborn respiratory distress syndrome. ( 15029631 )
2004
9
The association between hyaline membrane disease and preeclampsia. ( 15507975 )
2004
10
Diagnostic imaging of hyaline membrane disease. ( 15587869 )
2004
11
Caesarean route of delivery and hyaline membrane disease: a hospital-based case-control study in Greater Beirut. ( 14629318 )
2003
12
Early administration of the second dose of surfactant (beractant) in the treatment of severe hyaline membrane disease. ( 11332171 )
2001
13
Surfactant therapy for hyaline membrane disease: the Chandigarh experience. ( 11418729 )
2001
14
Hyaline membrane disease in a term neonate. ( 11563254 )
2001
15
Regulation of pro-inflammatory cytokine expression by curcumin in hyaline membrane disease (HMD). ( 12005259 )
2001
16
Surfactant deficiency in hyaline membrane disease: the story of discovery. ( 10764292 )
2000
17
Interleukin-8 expression by fetal and neonatal pulmonary cells in hyaline membrane disease and amniotic infection. ( 10960493 )
2000
18
Effects of inhaled nitric oxide on gas exchange and acute lung injury in premature lambs with moderate hyaline membrane disease. ( 10973544 )
2000
19
Continuous tracheal gas insufflation in preterm infants with hyaline membrane disease. A prospective randomized trial. ( 10988090 )
2000
20
Radiological analysis of hyaline membrane disease after exogenous surfactant treatment. ( 9880619 )
1999
21
Differential regulation of IL-8 by IL-1beta and TNFalpha in hyaline membrane disease. ( 9475356 )
1998
22
Inhaled nitric oxide neither alters oxidative stress parameters nor induces lung inflammation in premature lambs with moderate hyaline membrane disease. ( 9535535 )
1998
23
The effects of IL-10 on proinflammatory cytokine expression (IL-1beta and IL-8) in hyaline membrane disease (HMD). ( 9683557 )
1998
24
Endothelin A receptor blockade decreases pulmonary vascular resistance in premature lambs with hyaline membrane disease. ( 9702910 )
1998
25
Hyaline membrane disease is underreported in a linked birth-infant death certificate database. ( 9736884 )
1998
26
Tracheal aspirate surface tension in babies with hyaline membrane disease: effects of synthetic surfactant replacement. ( 9773912 )
1998
27
Continuous tracheal gas insufflation enables a volume reduction strategy in hyaline membrane disease: technical aspects and clinical results. ( 9840243 )
1998
28
New-born infants with severe hyaline membrane disease: radiological evaluation during high frequency oscillatory versus conventional ventilation. ( 9881260 )
1998
29
Surfactant treatment may accelerate epithelial cell regeneration in hyaline membrane disease of the newborn. ( 9890252 )
1998
30
Randomised controlled trial of low dose fentanyl infusion in preterm infants with hyaline membrane disease. ( 10194990 )
1998
31
Changes in anti-oxidant enzymes and lipid peroxidation in hyaline membrane disease. ( 10773913 )
1998
32
Effects of inhaled nitric oxide on pulmonary edema and lung neutrophil accumulation in severe experimental hyaline membrane disease. ( 9098845 )
1997
33
Pregnancy-induced hypertension and hyaline membrane disease. ( 9252255 )
1997
34
Bilateral multicystic kidney dysplasia in a fetus with neonatal pulmonary hyaline membrane disease: a case report. ( 9509666 )
1997
35
The effects of surfactant on haemodynamics in hyaline membrane disease. ( 9135282 )
1997
36
Lung function and airway responsiveness in children and adolescents after hyaline membrane disease: a matched cohort study. ( 9150328 )
1997
37
Pulmonary function in infants with neonatal chronic lung disease with or without hyaline membrane disease at birth. ( 9230255 )
1997
38
Hyaline membrane disease (HMD) therapy in Latin America: impact of exogenous surfactant administration on newborn survival, morbidity and use of resources. ( 9288665 )
1997
39
Undetectable interleukin (IL)-10 and persistent IL-8 expression early in hyaline membrane disease: a possible developmental basis for the predisposition to chronic lung inflammation in preterm newborns. ( 8725256 )
1996
40
Hyaline membrane disease. ( 8778912 )
1996
41
Effects of increased red cell mass on subclinical tissue acidosis in hyaline membrane disease. ( 8949689 )
1996
42
Serial assessment of ductus arteriosus hemodynamics in hyaline membrane disease. ( 8951268 )
1996
43
Effect of ductal patency on organ blood flow and pulmonary function in the preterm baboon with hyaline membrane disease. ( 8001369 )
1995
44
Hyaline membrane disease. ( 8597849 )
1995
45
Validation of a nitrogen washout system to measure functional residual capacity in premature infants with hyaline membrane disease. ( 8649921 )
1995
46
Intraairway Feulgen-positive bodies in hyaline membrane disease of the newborn. ( 8736600 )
1995
47
Assisted ventilation for hyaline membrane disease. ( 8772883 )
1995
48
Timing of transfer of babies with hyaline membrane disease from regional centres to level 3 nurseries. ( 8924318 )
1995
49
Inhaled nitric oxide improves gas exchange and lowers pulmonary vascular resistance in severe experimental hyaline membrane disease. ( 7808839 )
1994
50
Morphology of pulmonary extralobar sequestration in neonatal death by hyaline membrane disease. ( 7808976 )
1994

Variations for Newborn Respiratory Distress Syndrome

ClinVar genetic disease variations for Newborn Respiratory Distress Syndrome:

6 (show all 22)
# Gene Variation Type Significance SNP ID Assembly Location
1 BRAF NM_004333.5(BRAF): c.1502A> G (p.Glu501Gly) single nucleotide variant Pathogenic/Likely pathogenic rs180177039 GRCh37 Chromosome 7, 140477806: 140477806
2 BRAF NM_004333.5(BRAF): c.1502A> G (p.Glu501Gly) single nucleotide variant Pathogenic/Likely pathogenic rs180177039 GRCh38 Chromosome 7, 140778006: 140778006
3 ABCC8 NM_000352.4(ABCC8): c.3517G> A (p.Val1173Met) single nucleotide variant Likely pathogenic rs141322087 GRCh37 Chromosome 11, 17426099: 17426099
4 ABCC8 NM_000352.4(ABCC8): c.3517G> A (p.Val1173Met) single nucleotide variant Likely pathogenic rs141322087 GRCh38 Chromosome 11, 17404552: 17404552
5 DES NM_001927.3(DES): c.407T> A (p.Leu136His) single nucleotide variant Uncertain significance rs397516695 GRCh37 Chromosome 2, 220283591: 220283591
6 DES NM_001927.3(DES): c.407T> A (p.Leu136His) single nucleotide variant Uncertain significance rs397516695 GRCh38 Chromosome 2, 219418869: 219418869
7 IGHMBP2 NM_002180.2(IGHMBP2): c.92G> A (p.Trp31Ter) single nucleotide variant Pathogenic rs863224880 GRCh37 Chromosome 11, 68673542: 68673542
8 IGHMBP2 NM_002180.2(IGHMBP2): c.92G> A (p.Trp31Ter) single nucleotide variant Pathogenic rs863224880 GRCh38 Chromosome 11, 68906074: 68906074
9 SYT2 NM_001136504.1(SYT2): c.1084_1089delTATGAC (p.Tyr362_Asp363del) deletion Likely pathogenic rs1057518805 GRCh37 Chromosome 1, 202566056: 202566061
10 SYT2 NM_001136504.1(SYT2): c.1084_1089delTATGAC (p.Tyr362_Asp363del) deletion Likely pathogenic rs1057518805 GRCh38 Chromosome 1, 202596928: 202596933
11 PMP22 NM_000304.3(PMP22): c.422T> G (p.Val141Gly) single nucleotide variant Uncertain significance rs1057518804 GRCh37 Chromosome 17, 15134295: 15134295
12 PMP22 NM_000304.3(PMP22): c.422T> G (p.Val141Gly) single nucleotide variant Uncertain significance rs1057518804 GRCh38 Chromosome 17, 15230978: 15230978
13 GJB2 NM_004004.5(GJB2): c.488T> C (p.Met163Thr) single nucleotide variant Conflicting interpretations of pathogenicity rs1273330603 GRCh37 Chromosome 13, 20763233: 20763233
14 GJB2 NM_004004.5(GJB2): c.488T> C (p.Met163Thr) single nucleotide variant Conflicting interpretations of pathogenicity rs1273330603 GRCh38 Chromosome 13, 20189094: 20189094
15 ABCC8 NM_000352.4(ABCC8): c.1793G> A (p.Arg598Gln) single nucleotide variant Likely pathogenic rs1344172059 GRCh38 Chromosome 11, 17430838: 17430838
16 ABCC8 NM_000352.4(ABCC8): c.1793G> A (p.Arg598Gln) single nucleotide variant Likely pathogenic rs1344172059 GRCh37 Chromosome 11, 17452385: 17452385
17 SFTPC NM_001172357.1(SFTPC): c.163C> T (p.Leu55Phe) single nucleotide variant Likely pathogenic GRCh37 Chromosome 8, 22020207: 22020207
18 SFTPC NM_001172357.1(SFTPC): c.163C> T (p.Leu55Phe) single nucleotide variant Likely pathogenic GRCh38 Chromosome 8, 22162694: 22162694
19 ABCA3 NM_001089.3(ABCA3): c.3200G> A (p.Gly1067Glu) single nucleotide variant Uncertain significance GRCh37 Chromosome 16, 2336773: 2336773
20 ABCA3 NM_001089.3(ABCA3): c.3200G> A (p.Gly1067Glu) single nucleotide variant Uncertain significance GRCh38 Chromosome 16, 2286772: 2286772
21 ABCA3 NM_001089.3(ABCA3): c.614-2A> G single nucleotide variant Likely pathogenic GRCh37 Chromosome 16, 2369843: 2369843
22 ABCA3 NM_001089.3(ABCA3): c.614-2A> G single nucleotide variant Likely pathogenic GRCh38 Chromosome 16, 2319842: 2319842

Expression for Newborn Respiratory Distress Syndrome

Search GEO for disease gene expression data for Newborn Respiratory Distress Syndrome.

Pathways for Newborn Respiratory Distress Syndrome

Pathways related to Newborn Respiratory Distress Syndrome according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.92 CXCL8 IL1B IL6 SFTPD
2 11.88 CXCL8 IL1B IL6 TF
3 11.82 CXCL8 IL1B IL6
4 11.75 CXCL8 IL1B IL6
5 11.73 CXCL8 IL1B IL6
6
Show member pathways
11.7 SFTPB SFTPC SFTPD
7 11.7 CXCL8 IL1B IL6 PLA2G2A
8 11.68 CXCL8 IL1B IL6
9 11.65 CXCL8 IL1B IL6
10 11.58 CXCL8 IL1B IL6
11 11.58 BRAF CXCL8 IL1B IL6
12
Show member pathways
11.49 CXCL8 IL1B IL6
13 11.41 CXCL8 IL1B IL6
14 11.34 CXCL8 IL1B IL6
15 11.32 CXCL8 IL1B IL6
16 11.29 ELANE IL6 PLG
17 11.06 CXCL8 IL1B IL6 SFTPC
18 10.87 CXCL8 IL6
19
Show member pathways
10.73 SFTPB SFTPC SFTPD
20
Show member pathways
10.56 ABCA3 SFTPB SFTPC SFTPD

GO Terms for Newborn Respiratory Distress Syndrome

Cellular components related to Newborn Respiratory Distress Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.8 CXCL8 ELANE F5 IL1B IL6 PLA2G2A
2 extracellular space GO:0005615 9.47 ABCA3 CXCL8 ELANE F5 IL1B IL6
3 secretory granule GO:0030141 9.46 ELANE IL1B PLA2G2A SCGB1A1
4 extrinsic component of external side of plasma membrane GO:0031232 9.43 PLG TF
5 clathrin-coated endocytic vesicle GO:0045334 9.43 SFTPB SFTPC SFTPD
6 lamellar body GO:0042599 9.4 SFTPB SFTPC
7 multivesicular body lumen GO:0097486 9.37 SFTPB SFTPC
8 alveolar lamellar body GO:0097208 9.32 ABCA3 SFTPB

Biological processes related to Newborn Respiratory Distress Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 respiratory gaseous exchange GO:0007585 9.5 SFTPB SFTPC SFTPD
2 positive regulation of glial cell proliferation GO:0060252 9.46 IL1B IL6
3 platelet degranulation GO:0002576 9.46 F5 PLG TF TTN
4 low-density lipoprotein particle remodeling GO:0034374 9.43 PLA2G2A PLA2G7
5 positive regulation of neuroinflammatory response GO:0150078 9.4 IL1B IL6
6 negative regulation of chemokine biosynthetic process GO:0045079 9.26 ELANE IL6
7 cellular protein metabolic process GO:0044267 9.23 ABCA3 F5 IL6 PLG SFTPB SFTPC
8 response to glucocorticoid GO:0051384 9.13 ABCA3 IL6 SCGB1A1
9 response to ozone GO:0010193 9.07 SCGB1A1

Sources for Newborn Respiratory Distress Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....